| Objective:Ovarian cancer is one of gynecological malignant tumors of three,85% to 90% of malignant epithelial tumors, due to the onset occult, more advanced stage when found, and the high recurrence rate, once the recurrence, the main purpose of the treatment to relieve symptoms and improve quality of life, extended as far as possible free survival of patients (disease-free interval, DFI) and overall survival. Surgery for the treatment of recurrent ovarian cancer value has not been determined, evidence and timing of surgery still controversial, chemotherapy, recurrent ovarian cancer has become the preferred treatment, but not satisfied with the clinical efficacy, some patients with advanced resistant due to their own situation is not worse by chemotherapy. Medroxyprogesterone acetate (MPA) in hormone-dependent tumors such as renal cancer, prostate cancer, breast cancer treatment has made a significant effect. The biological activity of progesterone combined with the PR generated, but clinical observation of ovarian tumors were found on the later stages of the other tumor cells is lower, often not positive PR, which is the use of progesterone to bring certain problems. Laboratory studies have shown MPA can be the role of non-PR-mediated pathway of ovarian epithelial cancer cells, promoting their apoptosis. This clinical study was observed (ex-fold) and efficient MPA in refractory patients with recurrent ovarian cancer adjuvant therapy, further clinical study progesterone refractory recurrent ovarian cancer in rats.Methods:The clinical follow-up to collect and present the August 2010 consultation in our hospital, not satisfied by the comprehensive treatment of refractory patients with recurrent epithelial ovarian cancer in 7 cases,5 cases of poorly differentiated serous adenocarcinoma III period,1 case of well differentiated serous adenocarcinoma III,1 case was borderline mucinous cystic gland tumors II period. All cases have been accepted norms of cytoreductive surgery and postoperative chemotherapy, the treatment effect are not satisfied to observe the given times during the grace tablet 250mg po qd with treatment, observed toxicity of chemotherapy in patients with serum hormone levels, survival quality and progress of cancer, were followed up for 6 months.Results:Immunohistochemistry showed pathology in 7 patients, only 1 case of PR express -ion was positive, the rest were negative. En tablet in March after taking times blood tests in patients with serum sex hormone levels, the results showed well differentiated adenocarcinoma of serum progesterone levels were higher than before the 0.18mmol/L, no more than six cases of serum progesterone levels; There were no significant changes in serum estradiol levels; 1 patient had slightly elevated serum FSH levels, as well differentiated adenocarcinoma, compared with the previous decline of more than 6 cases were still at normal levels in postmenopausal women. All patients and living chemotherapy toxicity than before the treatment significantly improved performance compared to nausea and vomiting was significantly reduced compared with the previous degree of bone marrow suppression and other mitigation, but there are different degrees of low back pain, to the symptomatic improvement after treatment.7 patients were followed up to April 2011, completed follow-up,6 stable disease,1 case of poorly differentiated patients with disease progression, radiological examination revealed liver metastasis, massive ascites.Conclusion:High progesterone as an advanced refractory ovarian cancer in the neoadjuvant treatment, in line with platinum-based chemotherapy can enhance the efficacy of chemotherapy and reduce side effects of chemotherapy, alone can delay disease progression to some extent, improve the quality of life, PR-negative patients may get better results. Integrative Medicine for a better survival rate of ovarian cancer patients improve to provide a wider space. |
PDF Full Text Request